The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.

We tried Shark's vast vacuum lineup and explored the effectiveness of features like lift-away pods, dirt detection, and ...

After hitting a record high in 2021, the number of biotech IPOs have fallen to a yearly average in the 20s, with most successful entries in the last few quarters involving companies with mid- to ...

The new skin care? Scalp care—or more specifically, a scalp “detox”…which, funnily enough, involves using more products, not less. For some of us, hair routines are as straightforward as ...

In this episode, Barry chats with Vertex Minerals (ASX:VTX) executive chairman Roger Jackson, who is now making that pivotal switch to production from the Reward gold mine in the firing Lachlan ...

Grand portraiture is a minefield for some noteworthy hair. Portraitists such as Thomas Gainsborough and Anthony Van Dyck paid ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

It's a cool start to the day under a mostly clear sky. Temperatures this Thursday afternoon are expected to be near 80° across the Mid-South. Rain chance: <10%. Winds: 10 mph. LOOKING AHEAD ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on ...

Plus, the government has made no secret of this in its forecasts, outlining it in the budget last May, and again in its mid-year budget update in December. And don't expect the budget to return to ...